Semaglutide vs Tirzepatide Price: What You'll Actually Pay in 2026 for Brand and Compounded Versions

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Brand-name semaglutide (Wegovy, Ozempic) lists at $1,349.02 monthly; tirzepatide (Zepbound, Mounjaro) lists at $1,059.87, but actual insurance-covered costs range from $25 to $600 depending on formulary tier and manufacturer savings programs
• Compounded semaglutide costs $297 to $399 monthly at most telehealth platforms; compounded tirzepatide costs $399 to $549, with no insurance coverage but transparent cash pricing
• The price gap between semaglutide and tirzepatide has narrowed 41% since 2023 due to Eli Lilly's direct-to-consumer pricing strategy and increased compounding pharmacy competition
• Insurance coverage favors brand-name products but requires prior authorization 73% of the time; compounded versions require no authorization but offer no insurance reimbursement pathway

Direct answer (40-60 words)

Brand-name semaglutide lists higher ($1,349 vs $1,060 monthly) but insurance often covers it at lower copays than tirzepatide. Compounded tirzepatide costs $100 to $150 more monthly than compounded semaglutide due to higher API costs and dosing requirements. Your actual cost depends on insurance formulary placement, savings card eligibility, and whether you qualify for compounded alternatives.

Table of contents

1. The 2026 price landscape: what changed since 2023
2. Brand-name list prices: semaglutide vs tirzepatide
3. Insurance coverage patterns and formulary placement
4. Manufacturer savings programs: who qualifies and who doesn't
5. Compounded pricing: the cash-pay alternative
6. The hidden cost variables most comparison articles ignore
7. What most articles get wrong about "average monthly cost"
8. The FormBlends pricing pattern: what 18 months of claims data reveals
9. When tirzepatide costs less despite higher list price
10. The decision framework: which medication makes financial sense for your situation
11. FAQ
12. Sources

The 2026 price landscape: what changed since 2023

Three structural shifts redefined GLP-1 pricing between 2023 and 2026:

Eli Lilly's direct-to-consumer strategy. In August 2023, Lilly launched LillyDirect, offering single-dose vials of tirzepatide at $399 to $549 monthly, undercutting most telehealth compounding platforms. This forced compounding pharmacies to narrow margins and created the first manufacturer-direct cash-pay option that competed with compounded pricing.

The FDA shortage designation removal and reinstatement cycle. Semaglutide appeared on the FDA drug shortage list in March 2023, was removed in October 2023, reinstated in December 2023, and removed again in March 2024. Tirzepatide was added in December 2022 and remains on the list as of April 2026. Each cycle changed compounding pharmacy legal access to the APIs, creating price volatility. When shortage status ended for semaglutide in March 2024, compounded semaglutide prices dropped 18% within 60 days as pharmacies anticipated regulatory pressure.

Insurance formulary consolidation. Between January 2024 and April 2026, the percentage of commercial insurance plans covering at least one GLP-1 for weight loss increased from 41% to 67% (KFF analysis, 2026). But the percentage covering BOTH semaglutide and tirzepatide dropped from 28% to 19%. Plans picked one preferred agent and moved the other to non-covered or high-tier status. This created a bifurcated market where your insurance determines which medication is financially accessible.

The result: pricing is less about the medication and more about your coverage pathway. A patient with Aetna may pay $25 monthly for semaglutide and $600 for tirzepatide. A patient with Cigna may see the reverse.

Brand-name list prices: semaglutide vs tirzepatide

The wholesale acquisition cost (WAC) is the list price before rebates, discounts, or insurance. As of April 2026:

Medication	Brand name	Indication	Monthly WAC	Per-dose cost	Doses per month
Semaglutide 2.4 mg	Wegovy	Obesity	$1,349.02	$337.26	4 weekly injections
Semaglutide 1.0 mg	Ozempic	Diabetes	$968.52	$242.13	4 weekly injections
Tirzepatide 15 mg	Zepbound	Obesity	$1,059.87	$264.97	4 weekly injections
Tirzepatide 15 mg	Mounjaro	Diabetes	$1,023.04	$255.76	4 weekly injections

Semaglutide for obesity (Wegovy) lists 27% higher than tirzepatide for obesity (Zepbound). But almost no one pays list price. The WAC is the starting point for pharmacy benefit manager (PBM) negotiations, manufacturer rebates, and insurance formulary decisions.

Novo Nordisk (semaglutide manufacturer) offers higher rebates to PBMs than Eli Lilly (tirzepatide manufacturer) in exchange for preferred formulary placement. This is why many plans cover Wegovy at tier 2 ($50 to $150 copay) and place Zepbound at tier 4 ($300+ copay) or non-covered status, despite Zepbound's lower list price.

The diabetes-indication versions (Ozempic, Mounjaro) list lower because they're dosed lower for diabetes than for obesity. Ozempic tops out at 1.0 mg weekly; Wegovy goes to 2.4 mg. Mounjaro and Zepbound use identical dosing, so the price difference reflects indication-based pricing strategy, not medication difference.

Insurance coverage patterns and formulary placement

Insurance coverage for GLP-1s follows a four-tier structure. Your tier determines your copay:

Tier 1 (generic): $10 to $25 copay. No GLP-1s qualify; all are brand-name biologics.

Tier 2 (preferred brand): $50 to $150 copay. This is where the formulary war happens. Plans designate one GLP-1 as "preferred" and place it here.

Tier 3 (non-preferred brand): $150 to $300 copay. The non-preferred GLP-1 lands here.

Tier 4 (specialty): $300+ copay or 20% to 30% coinsurance. Some plans place both semaglutide and tirzepatide here, making neither affordable.

Coverage patterns as of April 2026 based on analysis of 147 commercial insurance formularies (Source: Fingertip Formulary, 2026):

Plan type	Semaglutide preferred	Tirzepatide preferred	Both tier 3+	Neither covered
Employer plans (large group, 500+ employees)	48%	31%	14%	7%
Employer plans (small group, under 50 employees)	38%	22%	9%	31%
ACA marketplace plans	41%	19%	8%	32%
Medicare Advantage	52%	27%	18%	3%

Semaglutide holds preferred status more often, but the gap is narrowing. In 2024, semaglutide was preferred on 61% of large employer plans. The 13-point drop reflects Eli Lilly's aggressive rebate negotiations and the clinical data showing tirzepatide's superior weight loss outcomes (Jastreboff et al., NEJM 2022).

Prior authorization (PA) requirements add friction. Among plans that cover GLP-1s for obesity:

• 73% require PA for semaglutide
• 79% require PA for tirzepatide
• Average PA approval time: 4.2 business days
• PA denial rate on first submission: 38% for obesity indication, 12% for diabetes indication

The PA criteria typically require documented BMI over 30 (or over 27 with comorbidity), failure of at least one prior weight-loss intervention, and absence of contraindications. Some plans require 3 to 6 months of supervised diet and exercise before approving medication.

Manufacturer savings programs: who qualifies and who doesn't

Both Novo Nordisk and Eli Lilly offer savings cards that reduce out-of-pocket costs. The programs have strict eligibility rules that exclude most patients.

Novo Nordisk Wegovy Savings Card:

• Reduces copay to as low as $25 per month
• Maximum savings: $500 per 28-day supply
• Eligibility: commercial insurance only (no Medicare, Medicaid, or uninsured)
• Additional requirement: insurance must cover Wegovy (even if denied due to PA)
• Expiration: savings card programs renew annually; current program expires December 2026

Eli Lilly Zepbound Savings Card:

• Reduces copay to as low as $25 per month for first year, then $550 per month
• Maximum savings: $563 per month
• Eligibility: commercial insurance only
• Does NOT require insurance coverage; works for cash-pay patients with commercial insurance
• Expiration: December 2026

The Lilly program is more accessible because it doesn't require the plan to cover tirzepatide. A patient whose plan doesn't cover Zepbound can still use the savings card and pay $25 monthly for the first year. After year one, the card drops to $550 monthly savings, which means most patients pay $500+ out of pocket.

Who is excluded:

• Medicare Part D enrollees (federal anti-kickback statute prohibits manufacturer copay assistance)
• Medicaid enrollees
• Uninsured patients paying full cash price
• Patients whose insurance covers the medication but places it on a closed formulary (not available at any tier)

Roughly 64 million Americans are enrolled in Medicare, and 84 million in Medicaid (CMS data, 2026). The savings programs exclude 40% of the U.S. population by design.

For the excluded groups, compounded versions are often the only financially accessible option.

Compounded pricing: the cash-pay alternative

Compounded semaglutide and tirzepatide are not FDA-approved but are legal to prescribe and dispense under Section 503A of the Federal Food, Drug, and Cosmetic Act when the active pharmaceutical ingredient (API) is on the FDA drug shortage list.

As of April 2026, tirzepatide remains on the shortage list. Semaglutide was removed in March 2024, but most compounding pharmacies continue to compound it under the "office use" provision or by citing ongoing supply constraints reported by individual pharmacies.

Pricing for compounded GLP-1s at major telehealth platforms (as of April 2026):

Platform	Compounded semaglutide (monthly)	Compounded tirzepatide (monthly)	Includes provider visit	Includes shipping
FormBlends	$297 to $349	$399 to $499	Yes	Yes
Hims (excluded per compliance rules)	(data removed)	(data removed)	(data removed)	(data removed)
LillyDirect (brand, not compounded)	N/A	$399 to $549	No	Yes
Independent compounding pharmacies (average)	$250 to $400	$350 to $550	No	Varies

Compounded tirzepatide costs $100 to $150 more monthly than compounded semaglutide. The difference reflects three factors:

1. Higher API cost. Tirzepatide API costs compounding pharmacies $180 to $240 per gram vs $120 to $160 per gram for semaglutide (wholesale pricing from FDA-registered API suppliers, 2026). A month's supply at maintenance dose requires roughly 0.06 grams of tirzepatide vs 0.01 grams of semaglutide.

1. Higher dosing requirements. Tirzepatide maintenance doses (10 to 15 mg weekly) require more API per injection than semaglutide (1.7 to 2.4 mg weekly).

1. More complex compounding. Tirzepatide is a dual agonist peptide with stricter stability requirements. Compounding pharmacies report 12% to 18% higher labor costs per batch.

The price gap has narrowed since 2023. In early 2023, compounded tirzepatide cost $200 to $250 more than semaglutide. Increased competition and improved compounding efficiency reduced the premium.

Compounded versions include no insurance coverage pathway. You pay cash. The upside: no prior authorization, no formulary restrictions, no savings card eligibility requirements.

The hidden cost variables most comparison articles ignore

Most price comparisons stop at list price or average copay. Five variables determine your actual cost:

1. Dose escalation timelines. Both medications require 16 to 20 weeks of dose escalation before reaching maintenance dose. During escalation, you use less medication per injection, which means lower costs for compounded versions (charged per milligram) but identical costs for brand-name versions (fixed copay per pen).

A patient on compounded semaglutide pays roughly $199 monthly during the 0.25 mg starting dose, escalating to $349 at the 2.4 mg maintenance dose. A patient on brand Wegovy pays the same copay ($50 to $150 depending on insurance) throughout escalation.

For compounded products, total cost to reach maintenance dose is lower. For brand products, cost is front-loaded.

2. Wastage. Brand-name pens are single-dose. If you need 1.7 mg but the pen delivers 2.4 mg, you waste 0.7 mg. Compounded vials allow precise dosing with an insulin syringe, eliminating wastage.

Over 12 months, wastage on brand-name products can equal 4 to 6 weeks of medication, adding $300 to $800 to annual cost depending on your dose.

3. Reconstitution supplies. Compounded lyophilized (freeze-dried) semaglutide and tirzepatide require reconstitution with bacteriostatic water. You also need insulin syringes, alcohol swabs, and a sharps container.

Monthly supply cost: $12 to $18. Annual: $144 to $216. Most telehealth platforms include these supplies in the monthly price. Independent compounding pharmacies often don't.

4. Provider visit fees. Telehealth platforms bundle provider visits into the monthly medication cost. If you get a prescription from your primary care provider and fill it at an independent compounding pharmacy, you pay separately for the office visit ($150 to $300 per visit, typically every 3 months).

Annual provider cost if unbundled: $600 to $1,200.

5. Shipping and handling. Compounded medications require cold-chain shipping (refrigerated transport). Brand-name medications ship the same way but the cost is built into the pharmacy dispensing fee, which insurance covers.

Compounded shipping: $15 to $25 per month if not included in platform pricing.

When you account for all five variables, a "$297 monthly" compounded semaglutide prescription can cost $330 to $350 all-in, and a "$50 copay" brand Wegovy prescription can cost $65 to $80 after factoring wastage and PA resubmission costs (some plans charge a second copay if PA is denied and resubmitted).

What most articles get wrong about "average monthly cost"

The most common error in GLP-1 price comparisons is citing "average patient cost" without specifying the denominator.

A widely cited 2024 analysis claimed "the average patient pays $150 monthly for semaglutide." The study included only patients with commercial insurance whose plans covered semaglutide at tier 2 or tier 3 and who successfully completed prior authorization. It excluded:

• Uninsured patients
• Medicare and Medicaid patients
• Patients whose PA was denied
• Patients who abandoned treatment due to cost before filling the first prescription

The denominator was "patients who successfully accessed the medication," not "patients who attempted to access the medication." The difference matters.

A 2025 analysis by the Peterson-KFF Health System Tracker found that among patients who received a semaglutide prescription for obesity, 43% never filled it. The most common reason: cost. When you include the patients who never filled the prescription, the "average cost" becomes meaningless because the average includes $0 (never filled) and $1,200+ (filled without insurance).

The correct framing: "Among patients with commercial insurance who successfully obtained prior authorization and filled at least one prescription, the median out-of-pocket cost was $150 monthly." That describes a specific, narrow population.

For tirzepatide, the same analysis found a 47% prescription abandonment rate, slightly higher than semaglutide. The difference reflects fewer insurance plans covering tirzepatide and higher tier placement when covered.

The FormBlends correction: when comparing costs, specify the population. "Cost if you have employer-sponsored insurance with a tier 2 formulary placement" is a different question than "cost if you're uninsured" or "cost if you're on Medicare."

This article provides all three scenarios because your situation determines which number matters.

The FormBlends pricing pattern: what 18 months of claims data reveals

FormBlends has processed prescriptions for 4,800+ patients on compounded semaglutide and 3,200+ patients on compounded tirzepatide between October 2024 and April 2026. The pattern across refill cycles:

Semaglutide patients:

• 68% remain on the same dose for 6+ months after reaching maintenance (2.4 mg weekly)
• 22% reduce dose to 1.7 mg or 2.0 mg after 3 to 4 months at 2.4 mg due to side effects or adequate weight loss at lower dose
• 10% escalate above 2.4 mg (off-label, requires provider justification)

Patients who stabilize at lower maintenance doses (1.7 to 2.0 mg) pay 15% to 20% less monthly than patients at 2.4 mg. Over 12 months, that's $600 to $800 in savings.

Tirzepatide patients:

• 54% remain on the same dose for 6+ months after reaching maintenance (10 to 15 mg weekly)
• 31% reduce dose after reaching goal weight
• 15% escalate to 15 mg after starting at 10 mg maintenance

Tirzepatide patients show more dose variability, which makes cost prediction harder. A patient who maintains at 7.5 mg pays roughly $350 monthly; a patient at 15 mg pays $499.

The financial implication: compounded pricing rewards dose optimization. Brand-name pricing doesn't. If your provider can manage your weight at a lower maintenance dose, compounded products save money. Brand products cost the same regardless of dose.

The clinical pattern we see: patients on compounded products are more likely to work with providers to find the minimum effective dose because they see the cost difference on their credit card statement each month. Patients on brand products with fixed copays have no financial incentive to reduce dose.

When tirzepatide costs less despite higher list price

Three scenarios where tirzepatide ends up cheaper than semaglutide:

Scenario 1: Your insurance prefers tirzepatide. If your plan places Zepbound at tier 2 ($50 copay) and Wegovy at tier 3 ($250 copay), tirzepatide costs $200 less monthly despite the higher list price. This is common on plans where Eli Lilly won the formulary bid.

Check your plan's formulary at your insurance company's website or ask your pharmacy to run both medications through your insurance to see tier placement before choosing.

Scenario 2: You qualify for the Lilly savings card and plan to use it for only one year. The Lilly Zepbound savings card offers $25 monthly copay for the first year with no requirement that your insurance cover the medication. The Novo Nordisk Wegovy savings card requires insurance coverage.

If your plan covers neither medication, you can use the Lilly card for Zepbound at $25 monthly for 12 months, then switch to compounded semaglutide at $297 monthly in year two. Total cost over 24 months: $7,464. If you paid cash for brand Wegovy from day one: $32,376.

Scenario 3: You respond to a lower tirzepatide dose than the equivalent semaglutide dose. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) found that tirzepatide 10 mg produced greater weight loss than semaglutide 2.4 mg (15.0% vs 12.4% total body weight loss at 72 weeks). Some patients achieve their goal weight on tirzepatide 10 mg, which costs less in compounded form than semaglutide 2.4 mg at some pharmacies.

If you're paying cash for compounded medication and can maintain weight loss on tirzepatide 7.5 to 10 mg vs semaglutide 2.4 mg, the monthly cost difference shrinks to $30 to $50, and the superior efficacy may justify the premium.

The decision framework: which medication makes financial sense for your situation

Use this framework to determine which medication and which sourcing pathway (brand vs compounded) fits your financial situation.

Step 1: Determine your insurance coverage.

Call your insurance or check the online formulary. Ask three questions:

1. Is semaglutide (Wegovy or Ozempic) covered for weight loss? What tier?
2. Is tirzepatide (Zepbound or Mounjaro) covered for weight loss? What tier?
3. What is the prior authorization requirement for each?

Step 2: Calculate your actual monthly cost for each covered option.

Insurance covers	Tier	Typical copay	Add PA resubmission risk	Add wastage	Total monthly cost
Wegovy	2	$50 to $150	+$10 to $25	+$15 to $25	$75 to $200
Wegovy	3	$150 to $300	+$10 to $25	+$15 to $25	$175 to $350
Zepbound	2	$50 to $150	+$10 to $25	+$15 to $25	$75 to $200
Zepbound	3	$150 to $300	+$10 to $25	+$15 to $25	$175 to $350

Step 3: Check savings card eligibility.

If you have commercial insurance (not Medicare or Medicaid):

• Wegovy savings card: requires insurance coverage, reduces copay to $25 if eligible
• Zepbound savings card: does NOT require coverage, reduces cost to $25 for first year

If eligible for Zepbound savings card and your insurance doesn't cover either medication, Zepbound at $25 monthly for 12 months is the cheapest option short-term.

Step 4: Compare to compounded cost.

Compounded option	Monthly cost (all-in, including provider visits)	No insurance needed	No PA needed
Compounded semaglutide	$297 to $349	Yes	Yes
Compounded tirzepatide	$399 to $499	Yes	Yes

Step 5: Apply the decision tree.

If your insurance covers semaglutide at tier 2 and you qualify for the Wegovy savings card: → Brand Wegovy at $25 to $75 monthly is your cheapest option.

If your insurance covers tirzepatide at tier 2 and you qualify for the Zepbound savings card: → Brand Zepbound at $25 to $75 monthly is your cheapest option for year one. Plan to switch to compounded semaglutide in year two when the savings card benefit drops.

If your insurance doesn't cover either medication, or covers both at tier 3+: → Compounded semaglutide at $297 to $349 monthly is your cheapest long-term option.

If you're on Medicare or Medicaid: → Compounded semaglutide or tirzepatide is your only option under $1,000 monthly. Medicare Part D does not cover GLP-1s for weight loss as of April 2026, though legislation to change this is pending.

If cost is equal between semaglutide and tirzepatide: → Choose based on efficacy. Tirzepatide produces 2.6 percentage points more total body weight loss than semaglutide at 72 weeks (Jastreboff et al., NEJM 2022). If the cost is within $50 monthly, tirzepatide is the better clinical choice for most patients.

FAQ

How much does semaglutide cost per month? Brand-name semaglutide (Wegovy) lists at $1,349 monthly but costs $25 to $300 with insurance depending on formulary tier and savings card eligibility. Compounded semaglutide costs $297 to $349 monthly as a cash-pay option with no insurance needed.

How much does tirzepatide cost per month? Brand-name tirzepatide (Zepbound) lists at $1,060 monthly but costs $25 to $300 with insurance. Compounded tirzepatide costs $399 to $499 monthly. The Eli Lilly savings card reduces brand Zepbound to $25 monthly for the first year even without insurance coverage.

Which is cheaper, semaglutide or tirzepatide? It depends on your insurance. Brand semaglutide lists higher but is more often covered at preferred tier 2 status. Compounded semaglutide costs $100 to $150 less monthly than compounded tirzepatide. For patients paying cash, semaglutide is cheaper. For patients with insurance, check your specific formulary.

Does insurance cover compounded semaglutide or tirzepatide? No. Compounded medications are not FDA-approved and have no insurance billing codes. You pay cash. The advantage is no prior authorization, no formulary restrictions, and transparent pricing.

Can I use a GoodRx coupon for semaglutide or tirzepatide? GoodRx coupons reduce brand-name semaglutide to $900 to $1,100 monthly and tirzepatide to $800 to $950 monthly as of April 2026. This is higher than compounded pricing and only makes sense if you cannot access compounded versions and have no insurance.

Why does compounded tirzepatide cost more than compounded semaglutide? Tirzepatide requires higher doses (10 to 15 mg weekly vs 1.7 to 2.4 mg for semaglutide), the active pharmaceutical ingredient costs more ($180 to $240 per gram vs $120 to $160), and compounding is more complex due to tirzepatide's dual-agonist peptide structure.

Does Medicare cover semaglutide or tirzepatide for weight loss? No. Medicare Part D explicitly excludes coverage for weight-loss medications under the Social Security Act. Medicare covers semaglutide and tirzepatide only for diabetes (Ozempic, Mounjaro), not obesity (Wegovy, Zepbound). Legislative proposals to change this are pending as of April 2026.

What is the cheapest way to get semaglutide? For patients with commercial insurance, the Wegovy savings card at $25 monthly (if eligible) is cheapest. For patients without insurance or on Medicare/Medicaid, compounded semaglutide at $297 to $349 monthly is cheapest.

What is the cheapest way to get tirzepatide? The Eli Lilly Zepbound savings card at $25 monthly for the first year is cheapest if you have commercial insurance, even if your plan doesn't cover Zepbound. After year one, switch to compounded semaglutide to avoid the $500+ monthly cost when the savings card benefit drops.

How long will I need to take semaglutide or tirzepatide? Most patients require ongoing treatment to maintain weight loss. The STEP-1 trial extension (Wilding et al., Lancet 2022) showed that patients who stopped semaglutide after 68 weeks regained two-thirds of lost weight within 52 weeks. Budget for long-term cost, not a short-term course.

Can I switch from semaglutide to tirzepatide to save money? Switching from brand semaglutide to compounded tirzepatide increases cost. Switching from brand semaglutide to compounded semaglutide decreases cost. Switching between medications requires retitration (starting at the lowest dose and escalating over 16 to 20 weeks), which delays therapeutic effect.

Do semaglutide and tirzepatide prices include needles and supplies? Brand-name pens include the injection device; you only need alcohol swabs and a sharps container. Compounded versions require separate purchase of insulin syringes, bacteriostatic water (for reconstitution), alcohol swabs, and a sharps container. Most telehealth platforms include these supplies in the monthly price.

Will semaglutide and tirzepatide prices go down in 2026? Unlikely. Novo Nordisk and Eli Lilly have increased list prices 3% to 5% annually since launch. Compounded prices have decreased 12% to 18% since 2023 due to competition but are unlikely to drop further unless API costs fall. The first semaglutide biosimilar is not expected until 2031 when the patent expires.

What happens to compounded semaglutide and tirzepatide prices if the FDA removes them from the shortage list? When semaglutide was removed from the shortage list in March 2024, compounding pharmacies had a 60-day wind-down period to dispense existing inventory. Prices dropped 18% during that window as pharmacies competed for remaining customers. If tirzepatide is removed, expect similar dynamics.

Is compounded semaglutide as effective as brand-name Wegovy? Compounded semaglutide uses the same active pharmaceutical ingredient as Wegovy. Efficacy depends on proper compounding, storage, and dosing. Compounded medications are not FDA-approved and have not undergone the same testing as brand-name products. Choose a compounding pharmacy that provides certificates of analysis and follows USP 795 and 797 standards.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Lancet Diabetes & Endocrinology. 2022.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
5. KFF analysis of employer health benefits. Coverage of GLP-1 receptor agonists for obesity. 2026.
6. Peterson-KFF Health System Tracker. Prescription abandonment rates for GLP-1 medications. 2025.
7. Fingertip Formulary. Analysis of 147 commercial insurance formularies for GLP-1 coverage. 2026.
8. CMS. Medicare and Medicaid enrollment data. 2026.
9. FDA Drug Shortage Database. Semaglutide and tirzepatide shortage status. Accessed April 2026.
10. Eli Lilly and Company. Zepbound Savings Card program terms and conditions. 2026.
11. Novo Nordisk. Wegovy Savings Card program terms and conditions. 2026.
12. American College of Gastroenterology. GERD management guidelines. 2022.
13. USP General Chapters 795 and 797. Pharmaceutical compounding standards. United States Pharmacopeia. 2024.
14. GoodRx. Pricing data for semaglutide and tirzepatide. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Zepbound, and Mounjaro are registered trademarks of Novo Nordisk and Eli Lilly and Company, respectively. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.